Adma Biologics Inc P / E
Was ist das P / E von Adma Biologics Inc?
P / E von Adma Biologics Inc ist 112.73
Was ist die Definition von P / E?
Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens je Aktie für die nächsten zwölf Monate.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P / E von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Adma Biologics Inc
Was macht Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Unternehmen mit p / e ähnlich Adma Biologics Inc
- Downing Four VCT DP67 hat P / E von 112.50
- Solitaire Machine Tools hat P / E von 112.51
- Ravindra hat P / E von 112.54
- Hooker Furnishings hat P / E von 112.64
- ELGI Equipments hat P / E von 112.71
- JSW hat P / E von 112.73
- Adma Biologics Inc hat P / E von 112.73
- Guangshen Railway hat P / E von 112.76
- Himadri Speciality Chemical hat P / E von 112.80
- Goenka Business & Finance hat P / E von 112.82
- Roots hat P / E von 112.90
- Oriental Hotels hat P / E von 112.90
- Lilly(Eli) & Co hat P / E von 112.99